TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:47
ASSEMBLY BIOSCIENCES INC. ( ASMB ) https://www.assemblybio.com
15.38USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ASMB
59.21%
SPY
32.66%
-43.29%
ASMB
SPY
108.59%
-93.88%
ASMB
SPY
302.52%
-83.67%
ASMB
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
97685.01
97591.50
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2394.01
3448.60
3756.68
26.01
0.00
-2182.57
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-160.06
100.00
-159.65
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.2336
-215.45
-48.98
0.52
Other Earnings and Cash Flow Stats:
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Net Income TTM ($MM) is -40.80
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Operating Income TTM ($MM) is -46.44
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Owners' Earnings Annual ($MM) is 22.37
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Current Price to Owners' Earnings ratio is 1.89
ASSEMBLY BIOSCIENCES INC. ( ASMB ) EBITDA TTM ($MM) is -46.26
ASSEMBLY BIOSCIENCES INC. ( ASMB ) EBITDA Margin is -159.65%
Capital Allocation:
ASSEMBLY BIOSCIENCES INC. ( ASMB ) has paid 0.00 dividends per share and bought back -6347.050556 million shares in the past 12 months
ASSEMBLY BIOSCIENCES INC. ( ASMB ) has increased its debt by 0.523 million USD in the last 12 months
Capital Structure:
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Interest-bearing Debt ($MM) as of last quarter is 1
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Annual Working Capital Investments ($MM) are 20
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Book Value ($MM) as of last quarter is 26
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Debt/Capital as of last quarter is 5%
Other Balance Sheet Stats:
ASSEMBLY BIOSCIENCES INC. ( ASMB ) has 28 million in cash on hand as of last quarter
ASSEMBLY BIOSCIENCES INC. ( ASMB ) has 41 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ASSEMBLY BIOSCIENCES INC. ( ASMB ) has 6351 common shares outstanding as of last quarter
ASSEMBLY BIOSCIENCES INC. ( ASMB ) has 0 million USD of preferred stock value
Academic Scores:
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Altman Z-Score is 777.37 as of last quarter
ASSEMBLY BIOSCIENCES INC. ( ASMB ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
ASSEMBLY BIOSCIENCES INC. ( ASMB ) largest shareholder is owning shares at 0.00 ($MM) value
GILEAD SCIENCES, INC.(an insider) Bought 940499 shares of ASSEMBLY BIOSCIENCES INC. ( ASMB ) for the amount of $20098463.63 on 2024-12-19
31.62% of ASSEMBLY BIOSCIENCES INC. ( ASMB ) is held by insiders, and 18.79% is held by institutions
ASSEMBLY BIOSCIENCES INC. ( ASMB ) went public on 2010-12-17
Other ASSEMBLY BIOSCIENCES INC. ( ASMB ) financial metrics:
FCF:22.82
Unlevered Free Cash Flow:30.07
EPS:-0.01
Operating Margin:-160.06
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-147.88
Beta:0.52
Buffet's Owners Earnings:22.37
Price to Owner's Earnings:1.89
About ASSEMBLY BIOSCIENCES INC. ( ASMB ) :
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.